DE60214207D1 - Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis - Google Patents
Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasisInfo
- Publication number
- DE60214207D1 DE60214207D1 DE60214207T DE60214207T DE60214207D1 DE 60214207 D1 DE60214207 D1 DE 60214207D1 DE 60214207 T DE60214207 T DE 60214207T DE 60214207 T DE60214207 T DE 60214207T DE 60214207 D1 DE60214207 D1 DE 60214207D1
- Authority
- DE
- Germany
- Prior art keywords
- tazarotes
- psoriasis
- prevention
- treatment
- nail polish
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000004681 Psoriasis Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 abstract 2
- 230000002682 anti-psoriatic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 229960000565 tazarotene Drugs 0.000 abstract 1
- 239000002966 varnish Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Paints Or Removers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0112825A FR2830449B1 (fr) | 2001-10-05 | 2001-10-05 | Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant |
| FR0112825 | 2001-10-05 | ||
| PCT/FR2002/003366 WO2003030896A1 (fr) | 2001-10-05 | 2002-10-03 | Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60214207D1 true DE60214207D1 (de) | 2006-10-05 |
| DE60214207T2 DE60214207T2 (de) | 2007-10-11 |
Family
ID=8867960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60214207T Expired - Fee Related DE60214207T2 (de) | 2001-10-05 | 2002-10-03 | Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050002878A1 (de) |
| EP (2) | EP1695707A1 (de) |
| JP (1) | JP2005505593A (de) |
| AT (1) | ATE337005T1 (de) |
| CA (1) | CA2462579A1 (de) |
| DE (1) | DE60214207T2 (de) |
| ES (1) | ES2271373T3 (de) |
| FR (1) | FR2830449B1 (de) |
| WO (1) | WO2003030896A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2329063C2 (ru) | 2002-09-05 | 2008-07-20 | Галдерма С.А. | Раствор для применения в области ногтей и околоногтевого пространства |
| DE10358091A1 (de) * | 2003-12-10 | 2005-07-14 | Eckart Gmbh & Co. Kg | Kosmetische Zusammensetzung zur Erzeugung eines kosmetischen Überzugs mit einem metallisch und mehrfarbig schillernden Erscheinungsbild und künstlicher Fingernagel |
| NZ598240A (en) * | 2009-07-16 | 2013-10-25 | Stiefel Laboratories | Tazarotene derivatives |
| US8492454B2 (en) | 2009-10-05 | 2013-07-23 | Creative Nail Design, Inc. | Removable color layer for artificial nail coatings and methods therefore |
| US8541482B2 (en) * | 2009-10-05 | 2013-09-24 | Creative Nail Design, Inc. | Removable multilayer nail coating system and methods therefore |
| US8263677B2 (en) * | 2009-09-08 | 2012-09-11 | Creative Nail Design, Inc. | Removable color gel basecoat for artificial nail coatings and methods therefore |
| KR20140016315A (ko) * | 2011-03-07 | 2014-02-07 | 크리에이티브 네일 디자인 인코포레이티드 | Uv-경화성 미용 손톱 코팅제를 위한 조성물 및 방법 |
| EP2612665A1 (de) | 2012-01-09 | 2013-07-10 | Almirall S.A. | Topische pharmazeutische Zusammensetzungen enthaltend Bexaroten und ein Kortikosteroid |
| CN107296809A (zh) * | 2016-04-15 | 2017-10-27 | 厦门恩成制药有限公司 | 一种治疗银屑病的外用药物组合物 |
| CN107468637A (zh) * | 2016-06-08 | 2017-12-15 | 厦门恩成制药有限公司 | 复方他扎罗汀尿素外用制剂及其制备方法 |
| KR102082761B1 (ko) * | 2018-10-22 | 2020-02-28 | 주식회사 대림 | 수용성 미네랄을 함유하는 화장품 조성물 및 그 제조방법 |
| CN120241598B (zh) * | 2025-04-29 | 2025-11-21 | 北京阳光诺和药物研究股份有限公司 | 一种抗真菌搽剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4250164A (en) * | 1979-04-09 | 1981-02-10 | Bernstein Joel E | Method of treating psoriasis of the nails and composition |
| DE4212105A1 (de) * | 1992-04-10 | 1993-10-14 | Roehm Pharma Gmbh | Nagellack zur Behandlung von Onychomykosen |
| ZA954599B (en) * | 1994-06-07 | 1996-01-26 | Allergan Inc | Stable gel formulation for topical treatment of skin conditions |
| CN1068524C (zh) * | 1997-06-23 | 2001-07-18 | 叶庆炜 | 一种治疗顽症牛皮癣的药物 |
| RO118174B1 (ro) * | 1997-08-21 | 2003-03-28 | Aventis Pharma Deutschland Gmbh | Lac de unghii şi utilizarea acestuia |
| US6231875B1 (en) * | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
| US6730308B1 (en) * | 1999-03-08 | 2004-05-04 | Allergan, Inc. | Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage |
| US6335023B1 (en) * | 1999-06-30 | 2002-01-01 | Ruey J. Yu | Oligosaccharide aldonic acids and their topical use |
-
2001
- 2001-10-05 FR FR0112825A patent/FR2830449B1/fr not_active Expired - Fee Related
-
2002
- 2002-10-03 EP EP06114290A patent/EP1695707A1/de not_active Withdrawn
- 2002-10-03 JP JP2003533928A patent/JP2005505593A/ja active Pending
- 2002-10-03 ES ES02800625T patent/ES2271373T3/es not_active Expired - Lifetime
- 2002-10-03 WO PCT/FR2002/003366 patent/WO2003030896A1/fr not_active Ceased
- 2002-10-03 CA CA002462579A patent/CA2462579A1/fr not_active Abandoned
- 2002-10-03 EP EP02800625A patent/EP1432414B1/de not_active Expired - Lifetime
- 2002-10-03 AT AT02800625T patent/ATE337005T1/de not_active IP Right Cessation
- 2002-10-03 DE DE60214207T patent/DE60214207T2/de not_active Expired - Fee Related
- 2002-10-03 US US10/491,666 patent/US20050002878A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2271373T3 (es) | 2007-04-16 |
| CA2462579A1 (fr) | 2003-04-17 |
| EP1432414A1 (de) | 2004-06-30 |
| DE60214207T2 (de) | 2007-10-11 |
| JP2005505593A (ja) | 2005-02-24 |
| EP1695707A1 (de) | 2006-08-30 |
| WO2003030896A1 (fr) | 2003-04-17 |
| US20050002878A1 (en) | 2005-01-06 |
| ATE337005T1 (de) | 2006-09-15 |
| FR2830449A1 (fr) | 2003-04-11 |
| EP1432414B1 (de) | 2006-08-23 |
| FR2830449B1 (fr) | 2004-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE50310516D1 (de) | Fredericamycin-derivate | |
| DE60327622D1 (de) | Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien | |
| CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
| DE60328476D1 (de) | Medizinisches ballonsystem zur behandlung von adipositas | |
| DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| ATE214933T1 (de) | Dermatologische zusammensetzungen, welche benzylneroxid und ein mittel zur verminderung von hautreizungen enthalten | |
| JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
| DE60136826D1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| ATE321048T1 (de) | Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes | |
| GB0223038D0 (en) | Therapeutic compounds | |
| DE60231804D1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen | |
| DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| ATE337005T1 (de) | Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis | |
| DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| NO20050450L (no) | Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft | |
| EE9900118A (et) | H+,K+-ATPaasi inhibiitorite kasutamine ninapolüüpide ravimisel | |
| ATE418552T1 (de) | Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
| DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
| ATE289196T1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
| ATE362923T1 (de) | 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen | |
| DE60027127D1 (de) | Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen | |
| ATE336992T1 (de) | Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz- erkrankungen | |
| DE60213234D1 (de) | 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts | |
| ATE206052T1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
| ATE482217T1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |